An FDA advisory panel concluded Friday that the abuse-resistant properties of Embeda, a morphine-based drug candidate from Alpharma, may be effective only in some patients, offering a small advantage over other pain medications. Some advisers expressed concern that labeling the product as tamper-proof could mislead physicians and patients because Alpharma tested Embeda's resistance only as an oral treatment.

Related Summaries